NEA Welcomes Scott Gottlieb, M.D., as Special Partner

Former FDA Commissioner Returns to Venture Capital Firm in New Role

Chevy Chase, MD – May 22, 2019New Enterprise Associates, Inc.(NEA), a leading global venture capital firm, today announced the appointment of Scott Gottlieb, M.D., as a Special Partner on the firm’s healthcare investment team. Dr. Gottlieb was a Venture Partner at NEA from 2007 to 2017 before being appointed the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), where he served from 2017 to 2019.

Under Dr. Gottlieb’s leadership, the FDA advanced new policies for the safe and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs, and digital health devices; implemented new reforms to standardize drug and medical device reviews; and promoted policies to reduce death and disease from tobacco, improve food innovation and safety, promote better nutrition, and aggressively confront addiction crises.

In addition to his role as an investor, Dr. Gottlieb is a physician, policy expert, and advocate for healthcare entrepreneurship, innovation, and access. He is focused on advancing public health to improve medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He helped oversee a modernization of the FDA’s new drug and medical device review programs and historic reorganization the agency’s field operations; and led the passage and implementation of significant new legislation, including new bills to address the opioid crisis and expand the agency’s user fee programs. He promoted new platforms for advancing medical product safety and presided over a 20 percent increase in the agency’s budget over two years.

“Throughout his prior 10-year tenure at NEA, Scott’s broad expertise was a tremendous asset for our healthcare practice and portfolio companies,” said David Mott, General Partner and Head of Healthcare Investing at NEA. “We are proud of his contributions to advancing innovation and increasing the quality of patient care as head of the FDA, and we’re thrilled to have him rejoin NEA, this time as a full-time investing partner. Scott will be based in our Chevy Chase, Maryland office and will be an active investor across the full spectrum of our healthcare activities, with a particular emphasis on biopharma and healthcare services. Scott is an invaluable resource for our entrepreneurs and our investing team as we work together to advance new products and services to better serve patients.”

Dr. Gottlieb is an elected member of the National Academy of Medicine and currently a Resident Fellow at the American Enterprise Institute (AEI) in Washington, DC. In addition to his recent role as FDA Commissioner, Dr. Gottlieb previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services.

Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. Earlier in his career, he worked as a healthcare analyst for the investment bank Alex. Brown & Sons. He completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.

In 2018 and again in 2019 Dr. Gottlieb was recognized by Fortune as one of "The World's 50 Greatest Leaders" and by Time as one of the “50 People Transforming Healthcare.” He is a CNBC contributor and his work is frequently published in a wide range of publications and medical journals, including The Wall Street Journal, The New York Times, and The Washington Post.

About NEA

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With more than $20 billion in cumulative committed capital since the firm’s first fund closed in 1978, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 225 portfolio company IPOs and more than 375 acquisitions.

# # #



Kate Barrett